Cipla Enters into a Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India
“Cipla” today announced it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This collaboration is a step further in Cipla’s efforts to enhance access to critical treatments for patients affected by the pandemic. Cipla will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets.
Lupin enters into Voluntary Licensing Agreement with Lilly to Expand Access for COVID-19 Treatment in India
Global pharma major, Lupin Limited (Lupin) today announced that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly’s drug Baricitinib in India. Lilly has received permission from Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for restricted emergency use of Baricitinib in combination with Remdesivir for the treatment of suspect or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients. With a rapid increase in active COVID-19 cases in India, the timely restricted emergency use of Baricitinib will be an important life-saving treatment for patients with moderate to severe symptoms of COVID-19.
Sun Pharma signs voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in India
“Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (“Lilly”) for expanding access to Lilly’s drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India. Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The drug is approved by the Central Drugs Standard Control Organization (CDSCO) for restricted emergency use in India.
TCS Positioned as a Leader in IDC MarketScape for Supply Chain SAP Ecosystems Services
“TCS continues to drive a global consulting-led approach that solves issues of board relevancy. We are helping customers de-risk their global supply chains and build greater resilience. Our SAP-centric SCM transformations harness TCS’ ecosystem and global scale, deep client contextual knowledge, SAP specific experience, and supply chain expertise to deliver adaptive, agile, intelligent and connected supply chains for our clients,” said Dave Jordan, Global Head, Consulting & Services Integration, TCS.
“This IDC MarketScape recognition is a reflection of our strategies, capabilities and the resultant market success.” TCS’ holistic consulting framework, TCS Enterprise Navigator™ drives business value and accelerates client's SAP-enabled SCM transformation journeys. It incorporates TCS Pace Port™, TCS Strategic Insights, preconfigured platforms, and perpetual transformation by leveraging the TCS Machine First™ Delivery Model. When leading SAP-enabled SCM transformations, TCS’ approach is to leverage industry specific accelerators, organizational change management methods and tools, and its deep contextual knowledge of its clients. This is further enabled by its strong 360-degree relationship with SAP with joint go to market, joint product development and beta testing, co-development around Model Company, and over 30 industry specific solutions. With this industry leading portfolio of intellectual property and one of the largest teams of SAP practitioners globally, TCS has become the preferred partner for enterprises looking to transform their supply chain management using SAP.
TCS’ Supply Chain practice envisions, designs, and builds digital enterprise supply networks which are adaptive, non-linear, omnidirectional, real-time sense and respond networks. TCS is advising, designing, and creating supply chain strategies for customers to operate in today’s environment while thinking and building for the future. TCS’ SAP-related services include design thinking, advisory, innovation consulting, implementation, and other digital support services. The company helps customers evaluate newer digital offerings such as SAP S/4HANA®, SAP Customer Experience solutions, SAP SuccessFactors® solutions, SAP Ariba® solutions, SAP Cloud Platform, and define their roadmap, architecture and strategy. TCS’ innovation and demo centers in Cincinnati-US, Paris-France, Mumbai-India and Tokyo-Japan help customers gain a first-hand experience of SAP’s new products and global innovations through a digital transformation ecosystem
Healthcare leader Dr Trust Announces New Addition to Senior Leadership Team
Nureca Limited, owner of the leading healthcare and wellness brand Dr Trust, is pleased to announce the appointment of Rohit Saini as its new Vice President of Sales and Marketing. Rohit brings to the position a wealth of knowledge and an array of experiences in the consumer healthcare industry.
Prior to his current role, Rohit was the General Manager Sales and Marketing (India and Sri Lanka) at Omron Healthcare India Pvt. Ltd. During his tenure, Rohit successfully lead a team of Sales and Marketing professionals across the Indian market. He was responsible for India Subcontinent P&L growth strategy with distribution of the KPls, he also devised ‘Above the Line’ and ‘Below the Line’ marketing strategies along with a 360 degree integrated marketing approach for Omron Healthcare. Rohit is 40 years old and brings over 19 years of experience. He has also served Coca Cola, Barry Callebaut, a Swiss Multinational and Ferrero India.
Aryan Goyal, CEO and Co-founder of Nureca, says he and Managing Director Saurabh Goyal, are delighted to have Rohit join Dr Trust. “Rohit’s background in sales, customer management, merchandizing, business development and research coupled with his outstanding interpersonal and communications skills will ensure that Dr Trust enjoys continued success, leads the health and wellness sector and is well positioned to take on new opportunities.”
Additionally, Rohit’s extensive sales background and business development skills should help Dr Trust strengthen channel partnerships, develop strategic alliances, expand our global and national sales presence and team building.” “lam very excited to be a part of the Nureca leadership team”, said Rohit Saini. “| look forward to building upon the company’s current successes and focusing on growing revenue rapidly.”